JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. District Court for the District of New Jersey has issued a decision in its litigation over the Company’s Abbreviated New Drug Application (ANDA) to market its generic version of AstraZeneca’s Seroquel® (Quetiapine) Tablets. The Court granted summary judgment in AstraZeneca’s favor on the issue of no inequitable conduct with regard to AstraZeneca’s U.S. Patent No. 4,879,288. Teva plans to appeal this decision.
